Journal article
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
Abstract
Importance: In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, there was a significant reduction in the adjudicated primary outcome among patients with stable atherosclerotic vascular disease randomized to dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily) vs aspirin monotherapy, but not with rivaroxaban 5 mg twice daily vs aspirin monotherapy. Whether the results are …
Authors
Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW
Journal
JAMA Network Open, Vol. 5, No. 11,
Publisher
American Medical Association (AMA)
Publication Date
November 1, 2022
DOI
10.1001/jamanetworkopen.2022.43201
ISSN
2574-3805